

Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

For the period: 1 January 2019 - 31 December 2019

Company:

Gilead Sciences Pty Ltd

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Hepatitis Australia	<p>Hepatitis Australia is a central partner in the national response to viral hepatitis working in close partnership with eight state and territory hepatitis organisations as well as other organisations and individuals who share the same vision to end to hepatitis B and hepatitis C in Australia. Key components of their work are their national policy and advocacy, provision of community information and education and support for hepatitis service delivery.</p> <p>The purpose of the grant was in supporting the development of collateral, media and communications associated with Hepatitis Australia's role as national coordinator of World Hepatitis Day (WHD) 2019. Hepatitis Australia manage <a href="http://www.worldhepatitisday.org.au">www.worldhepatitisday.org.au</a> and use their social media accounts &amp; strategic advertising to promulgate messages. They also develop and provide collateral &amp; other assistance to members, partners and individuals to promote WHD viral hepatitis messages at a local level across the country.</p>	30000
Hepatitis Victoria	<p>LiverWeLL trading as Hepatitis Victoria is the peak not-for-profit community organisation working across the state for people affected by or at risk of viral hepatitis and liver disease. Their vision at Hepatitis Victoria is a Victorian community where there are no new infections of viral hepatitis, and where those who have the virus are able to maximise their health and wellbeing.</p> <p>The Grant provided support to increase understanding of liver disease and NASH for liver patients and the general population; increase ability of the target group through appropriate channels to access testing and treatment for NASH; reduce misunderstanding and stigma around NASH; increase culture of health improvement and awareness of liver health through the output of research, consumer engagement and focus testing, resource production, online and print distribution of resources, Hepatitis Infoline, digital platforms such as website &amp; social media accounts, and</p>	8125

Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

For the period: 1 January 2019 - 31 December 2019

Company:

Gilead Sciences Pty Ltd

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Hepatitis WA	<p>HepatitisWA (Inc) is a non-profit community-based organisation providing free services to the community. HepatitisWA aims to assist in obtaining the best possible care and support for people affected by hepatitis, reducing discrimination and stigma directed at people living with viral hepatitis and raising community awareness in relation to hepatitis.</p> <p>The Grant provided in support to fund partnering with pharmacy teams in data identified hepatitis hotspots across the state, HepatitisWA aims to put information in the form of an education flyer on risk and testing for hep C directly into the hands of community members in priority populations when they access their local pharmacy for an unrelated health issues. The flyer will act as a resource that lists risk factor of exposure to Hep C that the general community may not be aware of - to prompt them to ask the health practitioner for testing.</p>	1000
National Association of people with HIV Australia (NAPWHA)	<p>The National Association of People with HIV Australia (NAPWHA) is Australia's peak non-government organisation representing community-based groups of people living with HIV (PLHIV)</p> <p>The Grant provided support to fund the NAPWHA HIV Criminalisation symposium which is a breakfast event running alongside the Australasian HIV Conference held in Perth. The symposium aims to bring together experts in HIV and criminalisation from multi-disciplinary professions from Australia and the region. The format offers topic based presentations and an opportunity to discuss the impact laws have on HIV transmission and HIV stigma and their impact on people living with HIV (PLHIV). Evidence shows criminalisation does not reduce HIV transmission, and the resulting stigma and discrimination</p>	20000

**Summary of Health Consumer Organisations supported by Medicines Australia Member Companies  
For the period: 1 January 2019 - 31 December 2019**

**Company: Gilead Sciences Pty Ltd**

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Rare Cancers Australia Ltd	<p>Rare Cancers Australia Ltd (RCA) is a registered Australian Charity, DGR Status 1, that was formed in 2012 with the mission to improve the lives and health outcomes of Australians living with a rare or less common cancer. RCA is committed to bringing affordable and equitable access to cancer medicines to all Australians regardless of the commonality of their disease.</p> <p>The Grant provided to the organisation supports the National Cancer Plan Vision 2030. RCA reached out to companies to assist in funding the foundation project that will form the basis of a much-needed Australian National Cancer Plan. The Project engages external consultants to engage in widespread stakeholder consultation and at the conclusion of which the project team will produce a report capturing the vision of cancer treatment in 2030.</p>	20000
Rare Cancers Australia Ltd	<p>Rare Cancers Australia Ltd (RCA) is a charity whose purpose is to improve the lives and health outcomes of Australians living with rare and less common (RLC) cancers.</p> <p>The Grant provided to the organisation supports funding following on from the highly successful "Just a Little More Time" Reports (JLMT) in 2014 and 2016. RCA intends to prepare and publish an updated version in 2019 that will contain expanded definitions of rare and rare subtypes and examine current treatment access. The report was launched in November in conjunction with the RCA CanForum and forms the centre-piece of an extended social and traditional media campaign. RCA undertook a major media campaign around the release of the report.</p>	25000